LEADER 05270nam 2200649Ia 450 001 9910817296903321 005 20200520144314.0 010 $a1-282-36283-6 010 $a9786612362835 010 $a0-470-68292-2 010 $a0-470-68291-4 035 $a(CKB)1000000000806579 035 $a(EBL)470600 035 $a(OCoLC)530178013 035 $a(SSID)ssj0000341795 035 $a(PQKBManifestationID)11278372 035 $a(PQKBTitleCode)TC0000341795 035 $a(PQKBWorkID)10396263 035 $a(PQKB)11030109 035 $a(MiAaPQ)EBC470600 035 $a(Au-PeEL)EBL470600 035 $a(CaPaEBR)ebr10346264 035 $a(CaONFJC)MIL236283 035 $a(EXLCZ)991000000000806579 100 $a20091008d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aPrinciples of CNS drug development $efrom test tube to patient /$fJohn Kelly 205 $a1st ed. 210 $aChichester, West Sussex ;$aHoboken, NJ $cJ. Wiley$d2009 215 $a1 online resource (326 p.) 300 $aDescription based upon print version of record. 311 $a0-470-51979-7 320 $aIncludes bibliographical references and index. 327 $aPrinciples of CNS drug development; Contents; Acknowledgements; Preface; Abbreviations; 1 Introduction; 1.1 The global burden of CNS disease; 1.2 Assessment of the global burden of disease; 1.3 The prevalence of CNS disorders; 1.4 Disability due to CNS disorders; 1.5 Economic Costs; 1.6 Concluding comments; References; 2 An overview of the major CNS disorders; 2.1 Introduction; 2.2 Overview of psychiatric disorders; 2.3 Overview of neurological/neurodegenerative disorders; 2.4 Concluding comments; References; 3 Neurobiological substrates of CNS disorders; 3.1 Introduction 327 $a3.2 Brief introduction to the principles of chemical neurotransmission3.3 Stages of chemical neurotransmission; 3.4 Approaches to investigating CNS alterations in CNS disorders; 3.5 Evidence for a neurobiological rationale for CNS disorders; 3.6 Concluding comments; References; 4 Current pharmacological targets; 4.1 Introduction; 4.2 Pharmacological treatments for depression; 4.3 Pharmacological treatments for schizophrenia; 4.4 Pharmacological treatments for anxiety disorders; 4.5 Pharmacological treatments for epilepsy; 4.6 Pharmacological treatments for Parkinson's disease 327 $a4.7 Pharmacological treatments for Alzheimer's disease4.8 Concluding comments; References; 5 Premarketing efficacy evaluation; 5.1 Introduction; 5.2 Target identification; 5.3 Lead optimisation; 5.4 Target validation in animal models; 5.5 The use of genetically modified animals in CNS drug development; 5.6 A selection of animal models of psychiatric disease; 5.7 A selection of animal models of neurodegenerative disease; 5.8 Which models to choose; 5.9 Clinical trials that evaluate drug efficacy; 5.10 Specific drug profiles; References 327 $a6 Pharmacokinetic considerations: Absorption, distribution, metabolism and elimination6.1 Introduction; 6.2 What are the 'ideal' pharmacokinetic properties for a CNS drug?; 6.3 Absorption; 6.4 Distribution; 6.5 Metabolism; 6.6 Elimination; 6.7 Measurement of drug concentrations; 6.8 Factors that affect pharmacokinetics; 6.9 Allometric scaling; 6.10 Microdosing (Phase 0) Studies; 6.11 Dose prediction and therapeutic drug monitoring; 6.12 Stereoselectivity of metabolism of drugs; 6.13 Specific drug profiles; 6.14 Concluding comments; References; 7 Safety concerns; 7.1 Introduction 327 $a7.2 Postmarketing surveillance7.3 Acute poisoning; 7.4 Quantification of the relative risk of fatalities from CNS drugs; 7.5 Adverse drug reactions (ADRs); 7.6 Specific types of toxicity encountered with psychotropic drugs; 7.7 Safety concerns following long-term administration of CNS Drugs; 7.8 Polypharmacy; 7.9 Specific drug profiles; 7.10 Concluding comments; References; Websites; 8 Preclinical and clinical safety evaluation; 8.1 Introduction; 8.2 Preclinical exploratory toxicology and safety pharmacology evaluations; 8.3 Primary and secondary pharmacology; 8.4 Safety pharmacology 327 $a8.5 Toxicology studies required for regulatory purposes 330 $aThis title acts as a primer, giving students and newcomers to the field an opportunity to learn about the breadth of the CNS drug discovery. The book outlines the core processes in drug discovery and development for CNS disorders, from evaluating drugs for desirable efficacy, safety and pharmacokinetic features in preclinical (using in vitro and in vivo models) and clinical experimentation to identifying future drug targets. Containing up-to-date experimental evidence and detailing the main impediments in the pipeline of CNS drug discovery and development, this is a key reference 606 $aNeuropharmacology 606 $aDrug development 615 0$aNeuropharmacology. 615 0$aDrug development. 676 $a615/.78 700 $aKelly$b John$f1961-$01705394 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910817296903321 996 $aPrinciples of CNS drug development$94092040 997 $aUNINA